Creso Pharma has signed a non-binding Letter of Intent (LOI) with Impactive Holdings to distribute the company’s suite of hemp CBD-based human health products, Cannadol and Cannaqix, in Canada and the US.
As part of the LOI, Creso will also obtain the rights to distribute Impactive’s CBD roller application in Switzerland and Europe.
Impactive is a Canadian company founded by current and former high-profile athletes who have struggled with injury and wanted to provide an alternative treatment route to the athletic community.
It has developed a range of CBD-based products designed to reduce muscle and joint
inflammation without the use of heavy narcotics or prescription pharmaceuticals. Its products are promoted by several well-known brand ambassadors.
Creso will target the growing sports and recreational market through a range of retail outlets.
The launch of Cannadol will be supported by high-profile influencer and two-time WFF world vice champion Jenny Dietschweiler, who said: “Cannadol brings substantial fast relief to joints and the muscles after intensive training. It enables faster high-performance and re-achievement.”
